Russia may recognize results of foreign clinical trials

27 January 2016

The Russian Ministry of Health is considering the proposal of the Federal Antimonopoly Service of the recognition of the results of clinical trials of drugs, conducted in the USA and the European Union in the territory of Russia, according to an official spokesman of Veronika Skvortsova, Russia’s Minister of Health, reports The Pharma Letter’s local correspondent.

Russia already recognizes the results of clinical studies of drugs conducted in foreign countries, which takes place "on the basis of reciprocity" and in the case of orphan drugs. According to state plans, this should create conditions for the expansion of the range of drugs in the Russian market.

According to Ms Skvortsova’s spokesman, some foreign pharmaceutical companies even refuse to launch their drugs in the Russian market as carrying out their clinical trials with the aim of further registration may take one-two years.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK